Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.4%.
In corporate news, Black Diamond Therapeutics (BDTX) shares jumped nearly 8%. The company and French pharmaceutical group Servier said Wednesday that they have signed a global licensing deal under which Servier will develop and globally commercialize BDTX-4933, a targeted therapy for solid tumors.
OmniAb (OABI) shares dropped 20% after it reported a Q4 net loss late Tuesday and gave 2025 revenue guidance that missed analysts' estimates.
Amarin (AMRN) shareholder JEC Capital Partners and some of its affiliates urged the company's board in an open letter Wednesday to undergo a strategic review to maximize shareholder value. Amarin shares popped past 6%.
HealthEquity (HQY) shares tumbled past 17% after its fiscal Q4 earnings fell short of market estimates, while it raised the top end of its full-year revenue outlook.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。